PROX1 and breast carcinoma: Thus, PROX-1 alone is unsuitable as a specific marker for LVD and LVI assessments in breast cancer, but it is really an indispensable marker in identifying mechanisms underlying tumor lymphangiogenesis and origins of LEC when combined with other markers [36,49].